Business

DATATRAK's Technology Driven Drug Development (TD3) Supports Clinical Trial Industry Transformation

DATATRAK's Technology Driven Drug Development (TD3) Supports Clinical Trial Industry Transformation.

articleDatatrak International, Inc.January 14, 20165/company/datatrak-international-inc/news/datatraks-technology-driven-drug-development-td3-supports-clinical-trial-industry-transformation
DATATRAK's Technology Driven Drug Development (TD3) Supports Clinical Trial Industry Transformation

About this update from Datatrak International, Inc.

[{"type":"text","content":"\nDATATRAK's Technology Driven Drug Development (TD3) Supports Clinical Trial Industry Transformation\n\nDATATRAK's Technology Driven Drug Development (TD3) Supports Clinical Trial Industry Transformation\n\n\nPatient-Focused Models, Improving Adherence, and Controlling Costs All Benefit From TD3\n\n\n CLEVELAND, OH--(Marketwired - January 14, 2016) - DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified dClinical™ technologies and delivering related services for the clinical trials industry, today announced that more than 100 CROs, 10 of the top 15 pharmaceutical organizations, and 3 top 10 biotechs, are using the DATATRAK ONE UX™ platform in their efforts to harness technology to drive drug development. \"Technology Driven Drug Development, TD3, is the concept that underlies all technology in DATATRAK's product solution portfolio. All of our customers look for every technological edge they can build into their processes. Maximizing the contribution of human and technological resources and consistently improving cost effectiveness is their daily routine. We're delighted that so many organizations are using the power of our DATATRAK ONE UX™ Platform to enable their success,\" said Laurence P. Birch, DATATRAK CEO. He continued, \"We're looking forward to helping the industry drive even greater efficiencies from patient-focused models, capturing big data, and using the resulting insight to increase the speed and efficacy of drug development.\"Tim Lyons, DATATRAK's Vice President of Product Development and Operations, stated that, \"Our strategic investments in technology are moving the bar to help clinical operations capitalize on the viability of their drug pipelines. The DATATRAK ONE UX™ platform's capability to improve and easily configure workflows can make a huge difference as companies work to mitigate risk via adaptive trial design and risk based monitoring.\"Contact DATATRAK today to schedule a demo and see for yourself how you can benefit from TD3.\n DATATRAK International, the leader in developing cloud-based, unified dClinical™ platform, is a worldwide technology and services company serving the clinical trials industry. The company delivers a portfolio of software solutions that safely accelerate clinical rese...

More updates from Datatrak International, Inc.